{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:33:57Z","timestamp":1761896037110},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T00:00:00Z","timestamp":1426723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s12253-015-9927-6","type":"journal-article","created":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T17:26:03Z","timestamp":1426699563000},"page":"1005-1011","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Computer Aided Semi-Automated Evaluation of HER2 Immunodetection\u2014A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy"],"prefix":"10.1007","volume":"21","author":[{"given":"Tam\u00e1s","family":"Micsik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Kiszler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Krecs\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba","family":"Heged\u0171s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kren\u00e1cs","family":"Tibor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9la","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,19]]},"reference":[{"issue":"4","key":"9927_CR1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/187569209790112337","volume":"7","author":"R Nahta","year":"2009","unstructured":"Nahta R, Shabaya S, Ozbay T, Rowe DL (2009) Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Pers Med 7(4):263\u2013274","journal-title":"Curr Pharmacogenomics Pers Med"},{"key":"9927_CR2","doi-asserted-by":"crossref","first-page":"903202","DOI":"10.4061\/2011\/903202","volume":"2011","author":"S Shah","year":"2011","unstructured":"Shah S, Chen B (2011) Testing for HER2 in breast cancer: a continuing evolution. Pathol Res Int 2011:903202. doi: 10.4061\/2011\/903202","journal-title":"Pathol Res Int"},{"issue":"8","key":"9927_CR3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/jcp.2011.089847","volume":"64","author":"JM Bartlett","year":"2011","unstructured":"Bartlett JM, Starczynski J, Atkey N, Kay E, O\u2019Grady A, Gandy M, Ibrahim M, Jasani B, Ellis IO, Pinder SE, Walker RA (2011) HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol 64(8):649\u2013653. doi: 10.1136\/jcp.2011.089847","journal-title":"J Clin Pathol"},{"issue":"1","key":"9927_CR4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","volume":"131","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18\u201343. doi: 10.1043\/1543-2165(2007)131[18:ASOCCO]2.0.CO;2","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"9927_CR5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/modpathol.2011.201","volume":"25","author":"L Arnould","year":"2012","unstructured":"Arnould L, Roger P, Macgrogan G, Chenard MP, Balaton A, Beauclair S, Penault-Llorca F (2012) Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH). Mod Pathol 25(5):675\u2013682. doi: 10.1038\/modpathol.2011.201","journal-title":"Mod Pathol"},{"issue":"3","key":"9927_CR6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1309\/97WN-W6UX-XJWT-02H2","volume":"118","author":"A Rhodes","year":"2002","unstructured":"Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ (2002) Evaluation of HER-2\/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 118(3):408\u2013417. doi: 10.1309\/97WN-W6UX-XJWT-02H2","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"9927_CR7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/14737159.8.6.707","volume":"8","author":"L Mulrane","year":"2008","unstructured":"Mulrane L, Rexhepaj E, Penney S, Callanan JJ, Gallagher WM (2008) Automated image analysis in histopathology: a valuable tool in medical diagnostics. Expert Rev Mol Diagn 8(6):707\u2013725. doi: 10.1586\/14737159.8.6.707","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"9927_CR8","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10549-012-2046-0","volume":"134","author":"YL Yang","year":"2012","unstructured":"Yang YL, Fan Y, Lang RG, Gu F, Ren MJ, Zhang XM, Yin D, Fu L (2012) Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance. Breast Cancer Res Treat 134(3):1095\u20131102. doi: 10.1007\/s10549-012-2046-0","journal-title":"Breast Cancer Res Treat"},{"key":"9927_CR9","first-page":"289","volume":"3","author":"CG Murphy","year":"2009","unstructured":"Murphy CG, Modi S (2009) HER2 breast cancer therapies: a review. Biologics 3:289\u2013301","journal-title":"Biologics"},{"issue":"3","key":"9927_CR10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00428-011-1132-8","volume":"459","author":"H Choritz","year":"2011","unstructured":"Choritz H, Busche G, Kreipe H (2011) Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch 459(3):283\u2013289. doi: 10.1007\/s00428-011-1132-8","journal-title":"Virchows Arch"},{"issue":"1","key":"9927_CR11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2559.2010.03577.x","volume":"57","author":"L Dobson","year":"2010","unstructured":"Dobson L, Conway C, Hanley A, Johnson A, Costello S, O\u2019Grady A, Connolly Y, Magee H, O\u2019Shea D, Jeffers M, Kay E (2010) Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation. Histopathology 57(1):27\u201338. doi: 10.1111\/j.1365-2559.2010.03577.x","journal-title":"Histopathology"},{"issue":"2","key":"9927_CR12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5858\/135.2.233","volume":"135","author":"MA Gavrielides","year":"2011","unstructured":"Gavrielides MA, Gallas BD, Lenz P, Badano A, Hewitt SM (2011) Observer variability in the interpretation of HER2\/neu immunohistochemical expression with unaided and computer-aided digital microscopy. Arch Pathol Lab Med 135(2):233\u2013242. doi: 10.1043\/1543-2165-135.2.233","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"9927_CR13","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2559.2011.04142.x","volume":"60","author":"VJ Tuominen","year":"2012","unstructured":"Tuominen VJ, Tolonen TT, Isola J (2012) ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry. Histopathology 60(5):758\u2013767. doi: 10.1111\/j.1365-2559.2011.04142.x","journal-title":"Histopathology"},{"issue":"5","key":"9927_CR14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/002215540305100503","volume":"51","author":"EM Brey","year":"2003","unstructured":"Brey EM, Lalani Z, Johnston C, Wong M, McIntire LV, Duke PJ, Patrick CW Jr (2003) Automated selection of DAB-labeled tissue for immunohistochemical quantification. J Histochem Cytochem 51(5):575\u2013584","journal-title":"J Histochem Cytochem"},{"issue":"5","key":"9927_CR15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1309\/Y73U8X72B68TMGH5","volume":"121","author":"K Bloom","year":"2004","unstructured":"Bloom K, Harrington D (2004) Enhanced accuracy and reliability of HER-2\/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol 121(5):620\u2013630. doi: 10.1309\/y73u-8x72-b68t-mgh5","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"9927_CR16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1309\/AJ84-50AK-1X1B-1Q4C","volume":"115","author":"HA Lehr","year":"2001","unstructured":"Lehr HA, Jacobs TW, Yaziji H, Schnitt SJ, Gown AM (2001) Quantitative evaluation of HER-2\/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol 115(6):814\u2013822. doi: 10.1309\/aj84-50ak-1x1b-1q4c","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"9927_CR17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.pai.0000150516.75567.13","volume":"14","author":"A Ciampa","year":"2006","unstructured":"Ciampa A, Xu B, Ayata G, Baiyee D, Wallace J, Wertheimer M, Edmiston K, Khan A (2006) HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system. Appl Immunohistochem Mol Morphol 14(2):132\u2013137. doi: 10.1097\/01.pai.0000150516.75567.13","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"9927_CR18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5858\/arpa.2011-0195-OA","volume":"136","author":"B Keller","year":"2012","unstructured":"Keller B, Chen W, Gavrielides MA (2012) Quantitative assessment and classification of tissue-based biomarker expression with color content analysis. Arch Pathol Lab Med 136(5):539\u2013550. doi: 10.5858\/arpa.2011-0195-OA","journal-title":"Arch Pathol Lab Med"},{"key":"9927_CR19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1746-1596-6-6","volume":"6","author":"L Krecsak","year":"2011","unstructured":"Krecsak L, Micsik T, Kiszler G, Krenacs T, Szabo D, Jonas V, Csaszar G, Czuni L, Gurzo P, Ficsor L, Molnar B (2011) Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer. Diagn Pathol 6:6. doi: 10.1186\/1746-1596-6-6","journal-title":"Diagn Pathol"},{"issue":"31","key":"9927_CR20","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997\u20134013. doi: 10.1200\/jco.2013.50.9984","journal-title":"J Clin Oncol"},{"issue":"1","key":"9927_CR21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159\u2013174","journal-title":"Biometrics"},{"issue":"10","key":"9927_CR22","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.5858\/2006-130-1440-ICOITF","volume":"130","author":"PL Fitzgibbons","year":"2006","unstructured":"Fitzgibbons PL, Murphy DA, Dorfman DM, Roche PC, Tubbs RR (2006) Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. Arch Pathol Lab Med 130(10):1440\u20131445. doi: 10.1043\/1543-2165(2006)130[1440:ICOITF]2.0.CO;2","journal-title":"Arch Pathol Lab Med"},{"key":"9927_CR23","doi-asserted-by":"crossref","first-page":"261857","DOI":"10.1155\/2012\/261857","volume":"2012","author":"V Martin","year":"2012","unstructured":"Martin V, Camponovo A, Ghisletta M, Bongiovanni M, Mazzucchelli L (2012) Internal Quality Assurance Program for ERBB2 (HER2) testing improves the selection of breast cancer patients for treatment with Trastuzumab. Pathol Res Int 2012:261857. doi: 10.1155\/2012\/261857","journal-title":"Pathol Res Int"},{"issue":"11","key":"9927_CR24","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/94.11.855","volume":"94","author":"PC Roche","year":"2002","unstructured":"Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94(11):855\u2013857","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9927_CR25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1309\/AJCPUQB18XZOHHBJ","volume":"134","author":"EE Grimm","year":"2010","unstructured":"Grimm EE, Schmidt RA, Swanson PE, Dintzis SM, Allison KH (2010) Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol 134(2):284\u2013292. doi: 10.1309\/AJCPUQB18XZOHHBJ","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"9927_CR26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00129039-200403000-00003","volume":"12","author":"J Andersson","year":"2004","unstructured":"Andersson J, Linderholm B, Bergh J, Elmberger G (2004) HER-2\/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol 12(1):14\u201320","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"9927_CR27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1066896906293055","volume":"14","author":"SJ Shin","year":"2006","unstructured":"Shin SJ, Hyjek E, Early E, Knowles DM (2006) Intratumoral heterogeneity of her-2\/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Int J Surg Pathol 14(4):279\u2013284. doi: 10.1177\/1066896906293055","journal-title":"Int J Surg Pathol"},{"issue":"5","key":"9927_CR28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/cyto.a.20374","volume":"71","author":"AS Joshi","year":"2007","unstructured":"Joshi AS, Sharangpani GM, Porter K, Keyhani S, Morrison C, Basu AS, Gholap GA, Gholap AS, Barsky SH (2007) Semi-automated imaging system to quantitate Her-2\/neu membrane receptor immunoreactivity in human breast cancer. Cytometry A 71(5):273\u2013285. doi: 10.1002\/cyto.a.20374","journal-title":"Cytometry A"},{"key":"9927_CR29","unstructured":"Health CfDaR (2007) 510(k) substantial equivalence determination decision summary for Aperio Technologies, Inc. ScanScope\u00ae XT System, IHC HER2\/neu Image Analysis Application. Food and Drug Administration. http:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K071128.pdf . Accessed 28 Mar 2013"},{"key":"9927_CR30","unstructured":"Health CfDaR (2004) 510(k) substantial equivalence determination decision summary for Applied Imaging Corporation, Applied Imaging Ariol\u2122 with HER2 Application. Food and Drug Administration. http:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf3\/k032113.pdf . Accessed 28 Mar 2013"},{"key":"9927_CR31","unstructured":"Health CfDaR (2003) 510(k) substantial equivalence determination decision summary for ChromaVision Medical Systems Inc. Automated Cellular Imaging System. . http:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K031715.pdf . Accessed 28 Mar 2012"},{"issue":"Suppl 1","key":"9927_CR32","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1186\/1746-1596-8-S1-S14","volume":"8","author":"TKG Micsik","year":"2013","unstructured":"Micsik TKG, Szab\u00f3 D, Krecs\u00e1k L, Kren\u00e1cs T, Moln\u00e1r B (2013) Is HER2 amplification predictable by digital immunohistochemistry? Diagn Pathol 8(Suppl 1):S14","journal-title":"Diagn Pathol"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-015-9927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-015-9927-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-015-9927-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T11:00:58Z","timestamp":1651575658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-015-9927-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,19]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["9927"],"URL":"https:\/\/doi.org\/10.1007\/s12253-015-9927-6","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,19]]}}}